. 2022 May 5;100(8):844–860. doi: 10.1111/aos.15159

Table 2.

Changes in HA treatment versus placebo in randomized double‐blinded placebo‐controlled trials, sorted by publication date.

First Author (year)	Design	Setup	Placebo arm	Duration	Symp.	TBUT	OSS	Schi.	Other outcomes
López‐de la Rosa A.^xo (López‐de la Rosa et al. ²⁰¹⁷)	16 moderate‐to‐severe DED	0.3% HA x3‐8/d	saline	1 mo x2	⟷	↑	⟷	⟷
Pinto‐Fraga J.^xo (Pinto‐Fraga et al. ²⁰¹⁷)	16 mild DED	0.2% HA x3‐8/d	saline	1 mo x2	↑	⟷	↑	⟷	↑ conjunctival hyperemia, ↑ subjective satisfaction
Baeyens V. (Baeyens et al. ²⁰¹²)	303 mild‐to‐moderate DED	0.18% HA x2‐4/d	saline	3 mo	↑/⟷	↑	↑	↑	↑ patient and investigator efficacy evaluation, ⟷ VA, ↑ blurry vision, less average drop instillations
Vogel R. (Vogel et al. ²⁰¹⁰)	436 moderate DED	0.18% HA x6/d	vehicle	2 w	↑		↑
Aragona P. Feb. 2002 (Aragona et al. ^2002b)	44 moderate‐to‐severe DED	0.15% HA x4‐8/d	saline	3 mo	⟷	⟷	⟷	⟷	↑ CIC
Condon P. I.^xo (Condon et al. ¹⁹⁹⁹)	70 KCS or SS	0.1% HA x3‐4/d	saline	1 mo x2	↑		↑	↑	3:1 patient preference for HA over saline
Shimmura S. (Shimmura et al. ¹⁹⁹⁵)	91 DED, SS	0.1% HA x6/d	vehicle	1 mo	⟷	⟷	↑/⟷	⟷^t	⟷ patient preference
Sand B. B.^xo (Sand et al. ¹⁹⁸⁹)	18 severe KCS	0.1% HA x6/d	vehicle	2 w x4	⟷	⟷	⟷	⟷	4/14 preferred 0.1% 8/14 preferred 0.2% 2/14 preferred placebo
Sand B. B.^xo (Sand et al. ¹⁹⁸⁹)	18 severe KCS	0.2% HA x6/d	vehicle	2 w x4	⟷	↑	↑	⟷

⟷ = no statistically significant difference compared to placebo with p > 0.05, ↑ = statistically significant improvement compared to placebo with p < 0.05, ↑/⟷ = statistically significant improvement with p < 0.05 compared to placebo in some but not all measures of this category, CIC = conjunctival impression cytology, d = day, DED = dry eye disease, HA = hyaluronic acid, KCS = keratoconjunctivitis sicca, mo = months, SS = Sjögren's syndrome, ^t = Schirmer's and tear clearance test, VA = visual acuity, w = weeks, ^xo = cross‐over study.